However, skin toxicities such as hand-foot skin reaction (HFSR) are primary side effects of these new multityrosine kinase inhibitors.
All published phase III trials, excluding abstracts without complete toxicity data, have reported grade 3 cutaneous reactions that require therapy modification and that probably affect the clinical benefits. [4] [5] [6] Although three decades have passed since HFSR was first described, the pathogenesis of and optimum therapeutic strategy for this skin toxicity remain largely unknown.
Bevacizumab is a recombinant humanized anti-VEGF monoclonal antibody that has proven beneficial in cancer therapy. It was ap- this finding indicates that the combination therapy may have a promising clinical application in the future.
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Although the results were encouraging, HFSR incidence was discovered to be higher when MKIs were combined with bevacizumab than when MKIs were used alone. Lee et al 11 demonstrated through a phase I trial that the HFSR incidence is higher in combination therapy with MKIs and bevacizumab than in monotherapy with MKIs, with all-grade and high-grade HFSR incidence rates of 94% and 56%, respectively. However, this finding was not conclusive because of limited enrolment of patients. Other researchers observed the same phenomenon. [8] [9] [10] Therefore, we conducted a meta-analysis and systematic review of the risk of developing HFSR when the combination therapy of
MKIs and bevacizumab was used to explore the safety of this therapy and to elucidate the pathogenesis of HFSR.
| RE SULTS

| Search results
A total of 78 potentially relevant citations were reviewed. Of the 35 articles identified by searching PubMed, 26 were excluded after review. Our search of American Society of Clinical Oncology (ASCO) abstracts yielded 43 potentially relevant studies, but none of these abstracts met the inclusion criteria. Finally, nine studies 7-15 that met the inclusion criteria were retrieved, including five phase I trials [9] [10] [11] 14, 15 and four phase II trials 7, 8, 12, 13 ( Figure 1 , Table 1 ). All were prospective single-arm studies. The sample sizes ranged from 14 to 54 (median sample size, 18 patients).
| Patients
Data from a total of 236 patients from the nine clinical trials were available for analysis. The baseline characteristics of the patients in the nine studies are listed in 
| Incidence of all-grade HFSR
All studies and all 236 patients had available data on all-grade HFSR for analysis. The reported incidences of all-grade HFSR ranged between 31.2% (5/16) and 79.4% (31/39). As shown in Figure 2A , the pooled incidence of all-grade HFSR in the 236 patients was calculated using the random-effects model (I 2 = 4.8%, P = .4) to be 56.9%
(95% CI, 45%-71.1%).
| Incidence of high-grade HFSR
All studies reported data on high-grade HFSR. High-grade HFSR was defined as grade 3 or grade 4, which can significantly impair patient functioning and affect treatment by necessitating dose reductions or treatment interruption. In our research, the incidence of high-grade HFSR in these studies ranged from 2.5% (1/39) to 33.3%
(5/15). As shown in Figure 2B , the pooled incidence of all-grade HFSR in the 236 patients was calculated using the random-effects model (I 2 = 28.1%, P = .2) to be 14.3% (95% CI, 9%-24.2%). in the ≥10 mg/kg group (95% CI, 38.7%-96.8%, I 2 = 0.0%, P = 1.0).
| Incidence of HFSR in patients treated with different doses of bevacizumab
The two groups were significantly different (P = .04; Table 2 ).
| Incidence of HFSR in patients with chemotherapy versus no chemotherapy
We explored whether chemotherapy affects the incidence of HFSR during treatment with MKIs and antiangiogenesis agents. In our search, three trials included chemotherapy in their regimen, whereas six did not. 3) in the no chemotherapy group. The two groups were significantly different (P = .5; Table 2 ).
| Difference in HFSR incidence between combination therapy and MKI monotherapy
We investigated the differences in HFSR incidence between combination therapy with MKIs and antiangiogenesis agents and monotherapy with MKIs, such as sorafenib, sunitinib, and pazopanib (incidences were all reported previously). [16] [17] [18] We used combination therapy as the control [with relative risk (RR) = 1] to calculate the RR of HFSR for each MKI. As shown in Table 3 
| Publication bias
As shown in Figure 3 , the funnel plot was optically symmetrical, indicating the absence of publication bias in this analysis.
| D ISCUSS I ON
Our analysis demonstrated that adding the antivascular endothelial growth factor antibody to MKI treatment significantly increases the risk of developing HFSR. The overall incidences of all-grade and high-grade HFSR (grade 3 and grade 4) with the combination therapy were 56.9% (95% CI, 45%-71.1%) and 14.3% (95% CI, 9%-24.2%), respectively. The incidences of all-grade and high-grade HFSR were significantly higher (P < .05, F I G U R E 2 Forest plot the incidence of (A) all-grade HFRS and (B) high-grade HFSR in patients with cancer randomly treated with combination MKIs and bevacizumab (64.3% vs 52.6%, P = .016) significantly increases HFSR incidence.
Meanwhile, combination with chemotherapy exerts a minimal effect on HFSR risk (61% vs 55.3%, P = .5). We only compared the 
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The pathogenesis of HFSR still remains unclear, but primary theories to explain HFSR have been developed based on clinical features and histopathologic findings. The most commonly accepted theory of HFSR pathogenesis contends that MKIs cause the syndrome at acral regions via a direct toxic effect. 20 HFSR can occur as early as 24 hours after drug administration, and a correlation between HFSR and MKI dosage was observed in most of the series and trials. A cellpoor lymphocytic interface dermatitis with basilar vacuolar degeneration and dyskeratosis, which is the most common histopathologic pattern observed, is also consistent with direct cytotoxic injury to the epidermis. 22, 29 However, evidence of the eccrine secretion of sorafenib and sunitinib onto the acral surface is still lacking, which argues against a direct toxic effect. Our analysis showed that HFSR incidence correlates with sorafenib dosage and that the incidence of HFSR is significantly higher with 400 mg BID than with 200 mg.
However, this finding is still insufficient to prove the hypothesis of direct toxic effect.
A previous study reported that combining antiangiogenic therapy with sorafenib and the VEGFR inhibitor bevacizumab increases the incidence and severity of HFSR. 11 Thus, HFSR may be the result of the direct inhibition of target receptors, specifically the dual blockade of VEGFR and PDGFR, in healthy tissue. 30 Given their inhibitory activities against multiple targets of VEGFR and PDGFR, sorafenib, sunitinib, and axitinib increase the risk of developing HFSR; in contrast, HFSR is not common when receptors are individually inhibited, as observed with the PDGFR inhibitor imatinib 31 or with small molecules and monoclonal antibodies that specifically target VEGFR. 32 The present study revealed that the combination therapy of MKIs and bevacizumab significantly increases the risk of HFSR depending on the bevacizumab dosage. Moreover, VEGFR is a critical factor but may not be the only factor that motivates HFSR.
This observation suggests that vascular endothelial injury is the leading cause of HFSR.
Although it provided useful information, this study cannot draw other conclusion aside from the fact that VEGFR contributes to the occurrence of HFSR. Chemotherapy exerted a minimal effect on HFSR incidence, suggesting that a direct toxic effect may not be the cofactor of VEGFR that leads to HFSR. This may be attributed to the concentration of drugs at acral regions being too low to stimulate injury. As mentioned previously, PDGFR may be the cofactor be- Finally, the results of this study may not be applicable to patients in a private or community setting because most of the patients in enrolled studies were involved in clinical trials performed in major institutions or academic centres.
In conclusion, combination therapy with MKIs and bevacizumab significantly increases HFSR risk. Therefore, using this 
| ME THODS
| Data sources
A systematic computerized search of the PubMed database was performed using the following keywords: multikinase inhibitor, VEGF inhibitor, sorafenib, regorafenib, axitinib, or pazopanib; antivascular endothelial growth factor, Avastin or bevacizumab; and hand-foot skin reaction or hand-foot syndrome. Abstracts presented at the ASCO Annual Meeting were also searched. Only papers published up to February 5, 2015, were considered. An independent search using the Web of Science database (a product developed by the Institute for Scientific Information, a citation database) was also conducted to ensure that no additional relevant studies were missed. All eligible studies were retrieved, and their bibliographies were checked for other relevant publications. When data were not available, efforts were exerted to contact the investigators. When the same patient population was used in several studies, only the largest and most recent publication was included in the meta-analysis.
| Study selection
The following criteria were used for study selection: (i) prospective phase I, II, and III clinical trials and expanded access programs in patients with any type of cancer; (ii) assignment of participants to treatment with a multikinase VEGF inhibitor (eg, sorafenib, regorafenib, axitinib, or pazopanib) and an antivascular endothelial growth factor agent (eg, bevacizumab); (iii) available data regarding events and incidence of HFSR; (iv) full papers published in the English language (abstracts were excluded because of insufficient data to evaluate the methodological quality of the study).
| Data extraction and clinical end point
The final articles included were independently assessed by two authors. Disagreements were resolved via discussion between these two authors. If they could not reach a consensus, another author was consulted to resolve the dispute, and a final decision was reached by majority vote. The clinical end points were extracted from the safety profile in each trial. HFSR incidence was recorded in accordance with the Common Terminology Criteria for Adverse Events, version 3.0. 42 In addition, the following data were collected from each study:
the name of the first investigator, the year of publication, the study design, the cancer type, the disease stage, and the treatment protocols. We included the incidences of all patients with HFSR grade ≥1.
The name of the lead investigator and the year of publication of the article were used for identification.
| Statistical analysis
For each study, the proportion of patients with HFSR was calculated, and the 95% CI was derived. The heterogeneity assumption was checked with the χ 2 -based Q test. A P value of more than 0.1 for the Q test indicates a lack of heterogeneity across studies. Different evaluation tools are developed due to the characteristics of different study types. Thus, in our study, the pooled incidence of HFSR was calculated using the fixed-effects model (Mantel-Haenszel model). Otherwise, the random-effects model (DerSimonian and Laird model) was used. 43, 44 Although metaanalysis has been used as an effective method to address a wide variety of clinical questions by summarizing and reviewing previously published quantitative research, several factors limit the quality of the results, due to publication bias, method of sampling, variations in genetic background of the subjects, and differences in the used protocols. 45 We aimed to minimize these limitations by using appropriate criteria to reduce selection bias, besides a funnel plot was used to estimate potential publication bias, with an asymmetric plot suggesting possible bias. A two-tailed P value < .05 was indicated statistical significance. All statistical tests were performed with STATA 13.0. 
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